Prognostic factors associated with major cytogenetic response and with survival in accelerated phase ± clonal evolution (N = 133)
| Parameter . | n . | Major cytogenetic response, n (%) . | P . | Survival at 2 y, % . | P . |
|---|---|---|---|---|---|
| Age | |||||
| Younger than 60 y | 91 | 39 (43) | .08 | 67 | .1 |
| 60 y or older | 42 | 11 (26) | 48 | ||
| Splenomegaly, cm bcm | |||||
| None | 69 | 37 (54) | 70 | ||
| 1-9 | 22 | 9 (41) | < .0001 | 69 | .08 |
| 10 or greater | 42 | 4 (10) | 44 | ||
| Hemoglobin | |||||
| Less than 10 g/dL | 62 | 18 (29) | .08 | 50 | .05 |
| 10 g/dL or more | 71 | 32 (45) | 72 | ||
| Platelets | |||||
| Less than 100 × 109/L | 53 | 22 (42) | 49 | ||
| 100-450 × 109/L | 38 | 14 (37) | .7 | 68 | .08 |
| Greater than 450 × 109/L | 42 | 14 (33) | 71 | ||
| Peripheral blasts | |||||
| None | 46 | 30 (65) | < .0001 | 72 | .2 |
| Any percentage | 87 | 20 (23) | 57 | ||
| Marrow blasts | |||||
| Less than 5% | 59 | 35 (59) | < .0001 | 68 | .2 |
| 5% or more | 74 | 15 (20) | 57 | ||
| Peripheral basophils | |||||
| Less than 7% | 75 | 32 (43) | .2 | 56 | .3 |
| 7% or more | 58 | 18 (31) | 68 | ||
| Marrow basophils | |||||
| Less than 5% | 61 | 26 (43) | .4 | 58 | .9 |
| 5% or more | 72 | 24 (33) | 64 | ||
| WBCs | |||||
| Less than 10 × 109/L | 44 | 23 (52) | 62 | ||
| 10-49 × 109/L | 61 | 21 (34) | .02 | 60 | 1.0 |
| 50 × 109/L or greater | 28 | 6 (21) | 62 | ||
| Sokal risk group | |||||
| Good | 21 | 9 (43) | 77 | ||
| Intermediate | 18 | 9 (50) | .4 | 70 | .07 |
| Poor | 20 | 6 (30) | 41 | ||
| Cytogenetic clonal evolution | |||||
| No | 82 | 33 (40) | .5 | 71 | .002 |
| Yes | 51 | 17 (33) | 46 | ||
| CML duration | |||||
| Shorter than 12 mo | 36 | 21 (58) | 69 | ||
| 12-35 mo | 37 | 13 (35) | .008 | 58 | .1 |
| 36 mo or longer | 60 | 16 (27) | 59 | ||
| Ph at start of therapy | |||||
| 90% or less | 13 | 10 (77) | .004 | 54 | .7 |
| More than 90% | 117 | 39 (33) | 62 |
| Parameter . | n . | Major cytogenetic response, n (%) . | P . | Survival at 2 y, % . | P . |
|---|---|---|---|---|---|
| Age | |||||
| Younger than 60 y | 91 | 39 (43) | .08 | 67 | .1 |
| 60 y or older | 42 | 11 (26) | 48 | ||
| Splenomegaly, cm bcm | |||||
| None | 69 | 37 (54) | 70 | ||
| 1-9 | 22 | 9 (41) | < .0001 | 69 | .08 |
| 10 or greater | 42 | 4 (10) | 44 | ||
| Hemoglobin | |||||
| Less than 10 g/dL | 62 | 18 (29) | .08 | 50 | .05 |
| 10 g/dL or more | 71 | 32 (45) | 72 | ||
| Platelets | |||||
| Less than 100 × 109/L | 53 | 22 (42) | 49 | ||
| 100-450 × 109/L | 38 | 14 (37) | .7 | 68 | .08 |
| Greater than 450 × 109/L | 42 | 14 (33) | 71 | ||
| Peripheral blasts | |||||
| None | 46 | 30 (65) | < .0001 | 72 | .2 |
| Any percentage | 87 | 20 (23) | 57 | ||
| Marrow blasts | |||||
| Less than 5% | 59 | 35 (59) | < .0001 | 68 | .2 |
| 5% or more | 74 | 15 (20) | 57 | ||
| Peripheral basophils | |||||
| Less than 7% | 75 | 32 (43) | .2 | 56 | .3 |
| 7% or more | 58 | 18 (31) | 68 | ||
| Marrow basophils | |||||
| Less than 5% | 61 | 26 (43) | .4 | 58 | .9 |
| 5% or more | 72 | 24 (33) | 64 | ||
| WBCs | |||||
| Less than 10 × 109/L | 44 | 23 (52) | 62 | ||
| 10-49 × 109/L | 61 | 21 (34) | .02 | 60 | 1.0 |
| 50 × 109/L or greater | 28 | 6 (21) | 62 | ||
| Sokal risk group | |||||
| Good | 21 | 9 (43) | 77 | ||
| Intermediate | 18 | 9 (50) | .4 | 70 | .07 |
| Poor | 20 | 6 (30) | 41 | ||
| Cytogenetic clonal evolution | |||||
| No | 82 | 33 (40) | .5 | 71 | .002 |
| Yes | 51 | 17 (33) | 46 | ||
| CML duration | |||||
| Shorter than 12 mo | 36 | 21 (58) | 69 | ||
| 12-35 mo | 37 | 13 (35) | .008 | 58 | .1 |
| 36 mo or longer | 60 | 16 (27) | 59 | ||
| Ph at start of therapy | |||||
| 90% or less | 13 | 10 (77) | .004 | 54 | .7 |
| More than 90% | 117 | 39 (33) | 62 |
bcm indicates below coastal margin.